×
Search your requirement
Search your requirement
Home
Press Releases
Submit Release
Events
Reach Us
Social media
Search
Home
Press Releases
Submit Release
Events
Reach Us
Search
Featured Press Releases
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
ProJenX announces the formation of its Clinical Advisory Board
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
Please enter the email address for your account. A verification code will be sent to you. Once you have received the verification code, you will be able to choose a new password for your account.
Email Address
*
Submit
Log in
Username
Show
Remember Me
Log in
Create an account
Forgot your username?
Forgot your password?
Most Popular
Algiax Pharmaceuticals expands AP-325 study in chronic neuropathic pain, adds 12 sites in Belgium and France
By
Algiax Pharmaceuticals GmbH
Apr 11
LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies
By
LIB Therapeutics Inc
May 29
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
By
Gilead Sciences, Inc.
Aug 20
May
2026
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
User Area
Login page
Registration
Edit Profile
Forgot Password
Discover
About Us
Terms Of Use
Privacy Policy
FAQs
Engage with Us
Search on Site
Post Press Release
Promote Brand
List Your Event
Subscribe to Our Monthly Newsletter
Subscribe to Pharmaceutical Era’s monthly newsletter,
Pharmaceutical Leaders Digest
®, to receive timely updates from across the pharmaceutical industry.
I agree with the
Terms and conditions
×
and the
Privacy policy
×
Please enable the javascript to submit this form
Subscribe
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click
here
.
I understand
